menu

Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Join us in this educational endeavor to empower pharmacists with the latest insights and strategies for improved decision-making in ATTR-CM management. The program emphasizes the latest clinical insights in this evolving therapeutic landscape, addressing changes in diagnostic approaches over the last decade, and providing a nuanced perspective on ATTR-CM progression for more effective patient care. Don’t miss out on this opportunity to elevate the standard of care for your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Hongya Chen, PharmD, BCCP
    Cardiology Clinical Pharmacist
    Oregon Health & Science University
    Portland, OR

    Dr. Chen has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: BMS, MyoKardia 

    Faculty:
    Jennifer L. Day, PharmD
    Clinical Transplant Pharmacist
    Baptist Health Heart Failure and Transplant Institute
    Little Rock, AR 

    Dr. Day has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Janssen Pharmaceuticals 

    Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
    Gerald S. Berenson Endowed Chair
    in Preventive Cardiology, Professor of Medicine
    Tulane University School of Medicine
    New Orleans, LA

    Dr. Ferdinand has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Amgen, Boehringer-Ingelheim, Eli Lilly, Medtronic, Janssen Pharmaceuticals 

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.  
    • Howard Green has nothing to disclose.  
    • Andrea Mathis has nothing to disclose.  
    • Tim Person has nothing to disclose.  
    • Mario Trucillo, PhD, MS, has nothing to disclose.
    • Toni Kramlik has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the pathophysiology and genetic variation of transthyretin amyloid cardiomyopathy (ATTR-CM) 
    • Discuss the clinical manifestations and diagnosis of ATTR-CM 
    • Compare the treatment options available for patients with ATTR-CM 
  • Target Audience

    This activity is designed to meet the educational needs of managed care pharmacists, primary care physicians, and advanced practice providers.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until May 22, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) designates this activity for 0.25 contact hours/0.025 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-051-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from BridgeBio.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Join us in this educational endeavor to empower pharmacists with the latest insights and strategies for improved decision-making in ATTR-CM management. The program emphasizes the latest clinical insights in this evolving therapeutic landscape, addressing changes in diagnostic approaches over the last decade, and providing a nuanced perspective on ATTR-CM progression for more effective patient care. Don’t miss out on this opportunity to elevate the standard of care for your patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Hongya Chen, PharmD, BCCP
    Cardiology Clinical Pharmacist
    Oregon Health & Science University
    Portland, OR

    Dr. Chen has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: BMS, MyoKardia 

    Faculty:
    Jennifer L. Day, PharmD
    Clinical Transplant Pharmacist
    Baptist Health Heart Failure and Transplant Institute
    Little Rock, AR 

    Dr. Day has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Janssen Pharmaceuticals 

    Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
    Gerald S. Berenson Endowed Chair
    in Preventive Cardiology, Professor of Medicine
    Tulane University School of Medicine
    New Orleans, LA

    Dr. Ferdinand has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Amgen, Boehringer-Ingelheim, Eli Lilly, Medtronic, Janssen Pharmaceuticals 

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.  
    • Howard Green has nothing to disclose.  
    • Andrea Mathis has nothing to disclose.  
    • Tim Person has nothing to disclose.  
    • Mario Trucillo, PhD, MS, has nothing to disclose.
    • Toni Kramlik has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the pathophysiology and genetic variation of transthyretin amyloid cardiomyopathy (ATTR-CM) 
    • Discuss the clinical manifestations and diagnosis of ATTR-CM 
    • Compare the treatment options available for patients with ATTR-CM 
  • Target Audience

    This activity is designed to meet the educational needs of managed care pharmacists, primary care physicians, and advanced practice providers.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until May 22, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.


    Global Learning Collaborative (GLC) designates this activity for 0.25 contact hours/0.025 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-051-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from BridgeBio.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule19 Jun 2024